Acute and long-term effects of peroxisome proliferator-activated receptor-α activation on the function and insulin secretory responsiveness of clonal beta-cells

Hormone and Metabolic Research

Volumn 43, Issue 4, 2011, Pages 244-249

  Irwin, N ^a   McKinney, J M ^a   Bailey, C J ^b   McClenaghan, N H ^a   Flatt, P R ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b ASTON UNIVERSITY   (United Kingdom)

Author keywords

AMPK; beta cell; insulin secretion; PPAR; rosiglitazone

Indexed keywords

ALANINE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL CLONE; CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; INCUBATION TIME; INSULIN LIKE ACTIVITY; INSULIN RELEASE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RAT;

ANIMALS; CELL LINE; CELL SURVIVAL; INSULIN; INSULIN-SECRETING CELLS; MICE; PPAR GAMMA; RATS; THIAZOLIDINEDIONES;

EID: 79953290826     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0030-1269897     Document Type: Article

References (36)

1. Stumvoll M. Thiazolidinediones - some recent developments. Expert Opin Investig Drugs 2003 12 1179-1187 (Pubitemid 36857206)
2. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995 270 12953-12956
3. Ye P, Fang H, Zhou X, He YL, Liu YX. Effect of peroxisome proliferator-activated receptor activators on tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes. Chin Med Sci J 2004 19 243-247 (Pubitemid 40128004)
4. Neschen S, Morino K, Dong J, Wang-Fischer Y, Cline GW, Romanelli AJ, Rossbacher JC, Moore IK, Regittnig W, Munoz DS, Kim JH, Shulman GI. n-3 Fatty acids preserve insulin sensitivity in vivo in a peroxisome proliferator- activated receptor-alpha-dependent manner. Diabetes 2007 56 1034-1041 (Pubitemid 46525082)
5. Wu HT, Chen W, Cheng KC, Yeh CH, Shen KH, Cheng JT. Indomethacin activates peroxisome proliferator-activated receptor to improve insulin resistance in cotton pellet granuloma model. Horm Metab Res 2010 42 775-780
6. Campbell IW, Mariz S. Beta-cell preservation with thiazolidinediones. Diabetes Res Clin Pract 2007 76 163-176
7. Dubois M, Pattou F, Kerr-Conte J, Gmyr V, Vandewalle B, Desreumaux P, Auwerx J, Schoonjans K, Lefebvre J. Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in normal human pancreatic islet cells. Diabetologia 2000 43 1165-1169
8. Fryer LG, Parbu-Patel A, Carling D. The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem 2002 277 25226-25232 (Pubitemid 34951829)
9. LeBrasseur NK, Kelly M, Tsao TS, Farmer SR, Saha AK, Ruderman NB, Tomas E. Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues. Am J Physiol Endocrinol Metab 2006 291 E175-E181 (Pubitemid 44035323)
10. Wang X, Zhou L, Shao L, Qian L, Fu X, Li G, Luo T, Gu Y, Li F, Li J, Zheng S, Luo M. Troglitazone acutely activates AMP-activated protein kinase and inhibits insulin secretion from beta cells. Life Sci 2007 81 160-165 (Pubitemid 46929110)
11. Richards SK, Parton LE, Leclerc I, Rutter GA, Smith RM. Over-expression of AMP-activated protein kinase impairs pancreatic beta-cell function in vivo. J Endocrinol 2005 187 225-235 (Pubitemid 41685182)
12. Tsuboi T, da Silva Xavier G, Leclerc I, Rutter GA. 5-AMP-activated protein kinase controls insulin-containing secretory vesicle dynamics. J Biol Chem 2003 278 52042-52051 (Pubitemid 38035789)
13. Sun G, Tarasov AI, McGinty J, McDonald A, da Silva Xavier G, Gorman T, Marley A, French PM, Parker H, Gribble F, Reimann F, Prendiville O, Carzaniga R, Viollet B, Leclerc I, Rutter GA. Ablation of AMP-activated protein kinase alpha1 and alpha2 from mouse pancreatic beta cells and RIP2. Cre neurons suppresses insulin release in vivo. Diabetologia 2010 53 924-936
14. Richardson H, Campbell SC, Smith SA, Macfarlane WM. Effects of rosiglitazone and metformin on pancreatic beta cell gene expression. Diabetologia 2006 49 685-696 (Pubitemid 43357542)
15. Lamontagne J, Pepin E, Peyot ML, Joly E, Ruderman NB, Poitout V, Madiraju SR, Nolan CJ, Prentki M. Pioglitazone acutely reduces insulin secretion and causes metabolic deceleration of the pancreatic beta-cell at submaximal glucose concentrations. Endocrinol 2009 150 3465-3474
16. Buettner R, Bettermann I, Hechtl C, Gäbele E, Hellerbrand C, Schölmerich J, Bollheimer LC. Dietary folic acid activates AMPK and improves insulin resistance and hepatic inflammation in dietary rodent models of the metabolic syndrome. Horm Metab Res 2010 42 769-774
17. McClenaghan NH, Barnett CR, Ah-Sing E, Abdel-Wahab YH, O'Harte FP, Yoon TW, Swanston-Flatt SK, Flatt PR. Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electrofusion. Diabetes 1996 45 1132-1140 (Pubitemid 26260168)
18. Hamid M, McCluskey JT, McClenaghan NH, Flatt PR. Comparison of the secretory properties of four insulin-secreting cell lines. Endocr Res 2002 28 35-47 (Pubitemid 34693137)
19. Flatt PR, Bailey CJ. Abnormal plasma glucose and insulin responses in heterozygous (ob/+) mice. Diabetologia 1981 20 573-577 (Pubitemid 11096955)
20. Diani AR, Sawada G, Wyse B, Murray FT, Khan M. Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes. Am J Physiol Endocrinol Metab 2004 286 E116-E122 (Pubitemid 38036617)
21. Kawasaki F, Matsuda M, Kanda Y, Inoue H, Kaku K. Structural and functional analysis of pancreatic islets preserved by pioglitazone in db/db mice. Am J Physiol Endocrinol Metab 2005 288 E510-E518 (Pubitemid 40250545)
22. Cox PJ, Ryan DA, Hollis JH, Harris AM, Miller AK, Vousden M, Cowley H. Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. Drug Metab Dispos 2000 28 772-780 (Pubitemid 30470827)
23. Winzell MS, Ahrén B. G-protein-coupled receptors and islet function-implications for treatment of type 2 diabetes. Pharmacol Ther 2007 116 437-448 (Pubitemid 350116941)
24. LeClerc I, Rutter GA. AMP-activated protein kinase: a new beta-cell glucose sensor?: Regulation by amino acids and calcium ions. Diabetes 2004 53 S67-S74 (Pubitemid 39564525)
25. Green BD, Irwin N, Duffy NA, Gault VA, O'Harte FP, Flatt PR. Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1. Eur J Pharmacol 2006 547 192-199 (Pubitemid 44373906)
26. Derosa G, Maffioli P, Ferrari I, Mereu R, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D'Angelo A, Salvadeo SA. Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients. Horm Metab Res 2010 42 663-669
27. Poitout V, Robertson RP. Glucolipotoxicity: fuel excess and beta-cell dysfunction. Endocr Rev 2008 29 351-366 (Pubitemid 351679704)
28. Lenzen S. Oxidative stress: the vulnerable beta-cell. Biochem Soc Trans 2008 36 343-347
29. Kanda Y, Shimoda M, Hamamoto S, Tawaramoto K, Kawasaki F, Hashiramoto M, Nakashima K, Matsuki M, Kaku K. Molecular mechanism by which pioglitazone preserves pancreatic beta-cells in obese diabetic mice: evidence for acute and chronic actions as a PPARgamma agonist. Am J Physiol Endocrinol Metab 2010 298 E278-E286
30. Blumentrath J, Neye H, Verspohl EJ. Effects of retinoids and thiazolidinediones on proliferation, insulin release, insulin mRNA, GLUT 2 transporter protein and mRNA of INS-1 cells. Cell Biochem Funct 2001 19 159-169 (Pubitemid 32768766)
31. Schinner S, Krätzner R, Baun D, Dickel C, Blume R, Oetjen E. Inhibition of human insulin gene transcription by peroxisome proliferator-activated receptor gamma and thiazolidinedione oral antidiabetic drugs. Br J Pharmacol 2009 157 736-745
32. Gupta D, Jetton TL, Mortensen RM, Duan SZ, Peshavaria M, Leahy JL. In vivo and in vitro studies of a functional peroxisome proliferator-activated receptor gamma response element in the mouse pdx-1 promoter. J Biol Chem 2008 21: 283 32462-32470
33. Zeender E, Maedler K, Bosco D, Berney T, Donath MY, Halban PA. Pioglitazone and sodium salicylate protect human beta-cells against apoptosis and impaired function induced by glucose and interleukin-1beta. J Clin Endocrinol Metab 2004 89 5059-5066 (Pubitemid 39391449)
34. Evans-Molina C, Robbins RD, Kono T, Tersey SA, Vestermark GL, Nunemaker CS, Garmey JC, Deering TG, Keller SR, Maier B, Mirmira RG. Peroxisome proliferator-activated receptor gamma activation restores islet function in diabetic mice through reduction of endoplasmic reticulum stress and maintenance of euchromatin structure. Mol Cell Biol 2009 29 2053-2067
35. Cnop M, Hannaert JC, Pipeleers DG. Troglitazone does not protect rat pancreatic beta cells against free fatty acid-induced cytotoxicity. Biochem Pharmacol 2002 63 1281-1285 (Pubitemid 34311996)
36. Kim SH, Abbasi F, Chu JW, McLaughlin TL, Lamendola C, Polonsky KS, Reaven GM. Rosiglitazone reduces glucose-stimulated insulin secretion rate and increases insulin clearance in nondiabetic, insulin-resistant individuals. Diabetes 2005 54 2447-2452 (Pubitemid 41134274)